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Are serial measurements of CAI9-9 useful in predicting
response to chemotherapy in patients with inoperable
adenocarcinoma of the pancreas?
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Summary Thirty-nine patients with inoperable adenocarcinoma of the pancreas were studied (27 male, 12 female; median age 60 years,
range 39-75 years). All patients received chemotherapy with continuous infusion 5-fluorouracil with intravenous bolus epirubicin followed by
cisplatin, repeated every 21 days for a total of six cycles and were evaluable for response. Serum CAl9-9 concentrations were obtained at
baseline and before each cycle. A rise or fall in the tumour marker was defined as a greaterthan 15% increase or decrease in the marker on
two consecutive occasions 3 weeks apart. A plateau in the tumour marker was defined as a less than 15% decrease or increase on two
occasions. Changes in marker expression were compared with serial computerized tomography scanning before treatment and afterthe third
and sixth cycle of chemotherapy. Thirty-five of 39 patients had an elevated CA19-9 (87.9%). Thirteen (36.2%) exhibited a decrease, seven
(19.4%) a plateau and 16 (44.4%) patients had a progressive rise in serum CAl9-9. The sensitivity of CAl9-9 was 67% for predicting a partial
response and 86%for progressive disease. The median survival forthe 13 patients exhibiting a reduction was 333 days, forthe seven patients
exhibiting a plateau 253 days and for those who had a progressive rise 185 days. The difference in median survival between the group of
patients with > 15% decrease and those with > 15% increase of CAl9-9 was significant (P= 0.001). In the cohort of patients who exhibited a
reduction in CAl9-9, no tumour progression was seen, and the reduction occurred during the first three cycles of treatment. Thus, interval
scanning may be avoided in this group of patients.
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Patients with adenocarcinoma of the pancreas have a particularly
poor survival with less than 1% alive 5 years from diagnosis.
Although it has been shown that patients who receive
chemotherapy tend to have a longer survival than a control group
receiving no treatment, the disease is relatively chemoresistant
(Palmer etal, 1994). The response rate, defined as a 50% reduction
in tumour size, is lower than that seen with other cancers and
assessment requires serial imaging, commonly using CT scanning.
Evaluation by this means can be difficult because of the high
proportion of fibrotic or inflammatory tissue relative to tumour,
which translates into a low response rate. In addition, it is expen-
sive and time-consuming.
Tumour markers represent a potentially simple and inexpensive
method of monitoring response. CA19-9 is the carbohydrate
antigen defined by monoclonal antibody 1116 NS 19-9 and is the
sialylated Lewisa blood group antigen (Koprowski et al, 1979).
Approximately 75% ofpatients with pancreatic carcinoma exhibit
elevated levels of serum CA19-9 at diagnosis, and it has been
shown to be more specific than carcinoembryonic antigen (CEA)
(Haglund et al, 1986). CAl9-9 levels greater than 100 u ml-1 have
a mean specificity of 98% for adenocarcinoma of the pancreas,
and thus it is considered to be the standard serum marker in the
management of this malignancy (Steinberg, 1990). Elevated
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preoperative levels have been found to correlate with a poor prog-
nosis, and markedly high concentrations (> 1000 u ml-') predict
for a low probability of surgical resection. Conversely, low preop-
erative levels predict abetter survival (Forsmark et al, 1994; Yasue
et al, 1994). An increase within 1 month of surgery is associated
with a poorer outcome (Haglund et al, 1986; Yasue et al, 1994),
whereas a fall predicts for a longer survival (Yasue et al, 1994).
Interestingly, a normal or raised CA19-9 level does not appear to
be independently predictive ofsurvival when correlated with stage
of disease, with no difference in survival being seen in patients
with stage I or IV disease (Lundin et al, 1994).
We set out to determine whether changes in CA19-9 concentra-
tions could be used to predict the response to chemotherapy in
patients with pancreatic cancer, as determined by conventional
WHO criteria of bidimensional diameter measurements of
tumours on radiological imaging.
PATIENTS AND METHODS
Thirty-nine patients referred for chemotherapy with inoperable
pancreatic cancer were studied; 27 were male and 12 female. The
median age was 60 years (range 39-75 years). Eighteen patients
had metastatic disease and 21 locally advanced disease. All
patients received chemotherapy with continuous infusion 5-fluo-
rouracil (5-FU) at a dose of 200 mg m-2 day-', with intravenous
bolus epirubicin (50 mg m-2) followed by cisplatin (60 mg m-2) on
day 1, repeated every 21 days for up to six cycles. All were evalu-
able for assessment ofresponse. The results ofourexperience with
the ECF (epirubicin, cisplatin, 5-FU) regimen in pancreatic cancer
have been published previously (Evans et al, 1996).
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Serum samples for tumour marker assessment were obtained at
baseline and before each cycle thereafter from all patients. The
serum CA19-9 concentration was measured using a commercially
available solid-phase enzyme immunoassay (CIS, France). The
normal value of < 37 u ml- for CA19-9 was set by the manufac-
turers based on excluding approximately 99% ofhealthy controls.
As obstruction of the common bile duct results in elevated CA19-
9, bilirubin levels were assessed concomitantly with CAl9-9
levels to ascertain that they were within normal limits (Paganuzzi
et al, 1988). Patients who becamejaundiced because of a blocked
stent between cycles ofchemotherapy were not excluded, as it has
previously been shown that, in cases in which CAl9-9 is abnormal
because of biliary stasis, resolution of the blockage allows
CA19-9 levels to return to the normal range within hours
(Arakama et al, 1985).
A rise or fall in the tumour marker was defined as a greater than
15% increase or decrease in the marker on two consecutive occa-
sions 3 weeks apart. A plateau in the tumour marker was defined
as a less than 15% decrease or increase on two occasions. For the
purposes ofthis study, a greater than 15% increase was considered
to be 'positive' with regard to the detection ofprogressive disease
and a greater than 15% decrease to be 'positive' for a response to
treatment, as previously described (Ward et al, 1993; Wong and
Chan, 1995). Tumours were assessed by computerized tomog-
raphy (CT) scanning before treatment and after the third and sixth
cycle of chemotherapy. Response evaluation was based on the
WHO criteria.
Changes in marker expression were compared with serial CT
scanning. Comparison of changes in tumour markers with CT in
patients achieving an objective response or progressive disease
were expressed in terms ofsensitivity, specificity and a positive or
negative predictive value. The following definitions apply:
Sensitivity:
Specificity:
true positive x 100%
(true positive + false negative)
true negative x 100%
(true negative + false positive)
Positive predictive value: truepositive x 100%
(true positive + false positive)
Negativepredictive value: truenegative x 100%
(true negative + false negative)
Survival curves were drawn using the Kaplan-Meier method
and analysed by the Wilcoxon rank test (Kaplan and Meier, 1958).
RESULTS
Thirty-five of 39 patients treated with ECF (87.9%) had an
elevated CAl9-9 greater than 37 u ml-l. Four patients had
normal pretreatment levels. In three patients, CA19-9 remained at
< 37 u ml-l during the whole course oftreatment; one had apartial
response, one stable disease and one progressive disease. It is
known that approximately 5% ofthe population do not express the
Lewisa antigen, which is in keeping with this observation. As these
patients were non-contributory, they were excluded from further
analysis. Of the 18 patients with metastatic disease, 94.4% had
elevated CAl9-9 serum levels at presentation compared with
85.7% with locally advanced tumours. Thirteen patients (36.2%)
exhibited a decrease in serial measurement of serum CA19-9
levels while receiving ECF chemotherapy (in ten the decrease in
tumour marker level was seen at the second cycle and in three at
the third cycle). Seven (19.4%) patients showed a plateau, and the
remaining 16 (44.4%) patients had a progressive rise in CA19-9.
Corresponding bilirubin levels were within normal limits.
Comparison between the trend in the marker and the CT find-
ings is shown in Table 1. The fall in CA19-9 was not sensitive in
the prediction of partial response (67%) and the specificity was
69%, resulting in a positive predicative value of only 30% and a
negative predictive value of 87%. Considering the prediction of
progressive disease, the sensitivity ofrising CA19-9 was 86%, but
the positive predictive value was only 37%. It has been argued that
CT assessment of metastatic lesions is more likely to demonstrate
a reduction in bidimensional measurements, and thus correlation
of changes in CA19-9 to CT changes was undertaken in the
subgroup of patients with metastatic disease. Unfortunately, no
partial remissions were seen in metastatic disease assessed either
by CT or by fall in CA19-9 levels, and thus the sensitivity and
positive predictive value for a fall in CA19-9 was 0%.
Median survival ofthe entire group of39 patients was 251 days
(range 54-459 days). The median survival for the 13 patients
exhibiting a reduction in CA19-9 was 333 days. For the seven
patients exhibiting a plateau, the median survival was 253 days
and for those patients who had a progressive rise in CA19-9 was
185 days. There was no significant difference in the overall
survival of patients with a reduction or plateau of CA19-9 or
reduction alone compared with those with a serial rise in the
tumour marker (P = 0.1) (Figure 1). However, the difference in
median survival of 185 days forthe patients with a > 15% increase
and 333 days for those with a > 15% decrease in tumour marker
was significant (P = 0.001) (Wilcoxon rank test). We have previ-
ously reported our experience using ECF in inoperable pancreatic
cancer (Evans et al, 1996). In this report, CT scans were used to
Table 1 Sensitivity, specificity and positive and negative predictive values of serial CA19-9 measurements in evaluating a partial response, stable or
progressive disease as demonstrated by CT scanning
Partial response Stable disease Progressive disease
Sensitivity (%) 4/6 (67) 6/23 (26) 6/7 (86)
Specificity (%) 20/29 (69) 12/16 (86) 18/29 (67)
Positive predictive value (%) 4/13 (30) 6/7 (86) 6/16 (37)
Negative predictive value (%) 20/23 (87) 12/29 (41) 18/20 (90)
British Journal ofCancer (1998) 77(2), 325-328 0CancerResearch Campaign 1998CA19-9 andresponse to chemotherapyin cancerofthepancreas 327
100-
~80
' 60
.0
co 40
20
20
0 200 400 600
Days
Figure 1 Survival curves comparing the survival of patients who
demonstrated a > 15% decrease in CA19-9 serum levels (closed symbols)
during ECF chemotherapy with those whose CAl9-9 levels increased by
> 15% (open symbols). Curves were drawn using the Kaplan-Meier method.
The median survival is significantly improved for patients with a fall in CAl9-9
(P = 0.001), although no patients survived for greater than 500 days
assess response, and these patients with either stable or responsive
disease had a significantly improved median survival (253 days)
compared with those with progressive disease (170 days). This is
very similar to the results presented here; a plateau or > 15%
decrease in CA125 was associated with a median survival of 271
days compared with 185 days for those with a > 15% increase.
DISCUSSION
Several tumour types, including ovarian, testicular, prostatic and
hepatocellular carcinomas, produce circulating antigens that have
proven to be useful in diagnosis, evaluation oftherapeutic outcome
and follow-up. The assessment of response by falling tumour
marker has been shown to be predictive of outcome in both testic-
ular and ovarian cancer (Beastall et al, 1991).
Previous studies assessing response of pancreatic cancer to
either endocrine therapy or chemotherapy using both CT scanning
and serum marker measurement have been less clear. Philip et al
(1993) treated 18 patients with an LHRH agonist in a phase II
study. Serial measurements of CA19-9 showed a steady rise in
serum concentrations in all patients, however none had a radiolog-
ical response and only two patients had stabilization ofthe disease
(Philip et al, 1993). In a study in which 82 patients with unre-
sectable carcinoma ofthe pancreas were treated with tamoxifen, it
was shown that, in patients who had a pretreatment CA19-9 level
greater than 37 u ml-', a prolonged survival was observed in those
who had a reduction or plateau compared with patients in whom
the pretreatment CA19-9 level was less than 37 u ml- and who
experienced a serial rise in the tumour marker (Wong and Chan,
1995). Only four studies using chemotherapy in patients with
pancreatic cancer have tried to correlate response with change in
CA19-9. Circadian rhythm-modulated 5-FUdR infusion with
Megace was used in the treatment of advanced pancreatic cancer.
In 13 patients, CA19-9 levels correlated extremely poorly with
disease status (De W Marsh et al, 1994). When radiotherapy was
used in combination with 5-FU modulated by leucovorin, ten
patients evaluable for response had baseline and post-treatment
CA19-9 levels that correlated with response (Schifeling et al,
1992). In the neoadjuvant setting using chemoradiation, a rise in
CA19-9 strongly correlated with progressive disease, but 21% of
patients with a fall in CA19-9 in fact had progressive disease
(Willet et al, 1996). Finally, in a phase II trial of gemcitabine in
patients with pancreatic cancer, 16 of 35 patients had prospective
assessment ofCAI9-9. Substantial decreases ofthe tumour marker
were seen in two patients with partial responses, in one patient
with stable disease and long duration of survival (> 60%), but
decreases of > 20% were seen in four out of seven patients with
progressive disease (Carmichael et al, 1996).
The aim of this study was to retrospectively assess the role of
CA19-9 in patients treated with combination chemotherapy for
inoperable pancreatic cancer, and in particular to assess whether
changes in the level ofCAl9-9 predicted response and/or survival.
In our study, we found the use ofCAl9-9 in monitoring the course
ofthe disease to be limited. Sensitivity and specificity percentages
were low, as was the positive predictive value ofthe test.
In the cohort of 13 patients who exhibited a reduction in CAI9-
9, however, no tumour progression was seen. For those patients
with stable disease and a serial decrease of CA19-9, this may be
explained on the basis that the treatment was having an inhibitory
effect on the tumour, which was insufficient to result in a response
on CT. This finding is also consistent with the results ofour phase
II study in which patients treated with ECF who achieved either
stable disease or partial response had a significantly improved
median survival compared with patients who progressed during
treatment (Evans et al, 1996). When comparing a reduction or
plateau in the tumour marker on treatment with a serial rise of
CAl9-9 concentration, no statistically significant difference in
overall survival was shown, although there was a 62% prolonga-
tion of median survival in the former group. The positive predic-
tive value of CA 19-9 level was not high enough to allow for
reliance on this tumour marker alone to assess response to therapy.
However, it may be possible to avoid interval scanning for those
patients with an elevated CA 19-9 at initiation of treatment who
show a > 15% reduction over the first 9 weeks oftreatment, as the
reduction occurred during the first three cycles oftreatment.
False-positive elevation of serum CA19-9 has been noted,
particularly in hepatobiliary diseases and chronic pancreatitis, and
it has been suggested that in patients with pancreatic cancer
obstruction ofthe common bile duct might contribute to the eleva-
tion of this tumour marker (Paganuzzi et al, 1988). However, all
CAl9-9 levels were matched to a concomitant bilirubin to ensure
biliary obstruction was not affecting the CA19-9 concentration.
In conclusion, CA19-9 may be of limited use as the primary
means of follow-up, providing it is elevated at baseline. This
strategy may reduce the number of scans performed on an indi-
vidual patient. However, it is clear that this tumour marker cannot
replace the use of imaging in the assessment of response in the
management ofpatients with pancreatic cancer, and more specific
and sensitive markers are required.
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